Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment. by Nguyen, Anh et al.
HAL Id: hal-00180710
https://hal.archives-ouvertes.fr/hal-00180710
Submitted on 20 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Nanoparticles loaded with ferrocenyl tamoxifen
derivatives for breast cancer treatment.
Anh Nguyen, Véronique Marsaud, Céline Bouclier, Siden Top, Anne Vessieres,
Pascal Pigeon, Ruxandra Gref, Philippe Legrand, Gérard Jaouen, Jack-Michel
Renoir
To cite this version:
Anh Nguyen, Véronique Marsaud, Céline Bouclier, Siden Top, Anne Vessieres, et al.. Nanoparticles
loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment.. International Journal of
Pharmaceutics, Elsevier, 2008, 347 (1-2), pp.128-35. ￿10.1016/j.ijpharm.2007.06.033￿. ￿hal-00180710￿
Nanoparticles loaded with ferrocenyl tamoxifen derivatives for 
breast cancer treatment 
 
Anh Nguyen 
b
, Véronique Marsaud 
a
, Céline Bouclier 
a
, Siden Top 
b
, Anne Vessieres 
b
, Pascal 
Pigeon 
b
, Ruxandra Gref 
a
, Philippe Legrand 
c
, Gérard Jaouen 
b
, Jack-Michel Renoir 
a
 
 
a
 Laboratoire de physico-chimie, pharmacotechnie, biopharmacie, UMR CNRS 8612 and IFR 
141, université Paris XI, 92296 Châtenay-Malabry, France 
b
 Laboratoire de chimie et biochimie des complexes moléculaires, UMR CNRS 7576, école 
nationale supérieure de chimie de Paris, 11, rue Pierre-et-Marie-Curie, 75231 Paris cedex 05, 
France 
c
 Institut Charles-Gerhardt UMR 5253 CNRS/UM2/ENSCM/UM1, équipe MACS, faculté de 
pharmacie, 15, avenue Charles-Flahault, B.P. 14491, 34093 Montpellier cedex 05, France 
 
Abstract 
For the first time, two organometallic triphenylethylene compounds (Fc-diOH and DFO), 
with strong antiproliferative activity in breast cancer cells, but insoluble in biological fluids, 
were incorporated in two types of stealth nanoparticles (NP): PEG/PLA nanospheres (NS) and 
nanocapsules (NC). Their physicochemical parameters were measured (size, zeta potential, 
encapsulation and loading efficiency), and their biological activity was assessed. In vitro drug 
release after high dilution of loaded NPs was measured by estradiol binding competition in 
MELN cells. The influence of the encapsulated drugs on the cell cycle and apoptosis was 
studied by flow cytometry analyses. Notwithstanding potential drug adsorption at the NP 
surface, Fc-diOH and DFO were incorporated efficiently in NC and NS, which slowly 
released both compounds. They arrested the cell cycle in the S-phase and induced apoptosis, 
whose activity is increased by loaded NS. A decrease in their antiproliferative activity by the 
antioxidant α-tocopherol indicated that reactive oxygen species (ROS) may be involved. 
Therefore, nanosystems, containing for the first time a high load of anticancer organometallic 
triphenylethylenes, have been developed. Their small size and delayed drug release, combined 
with their enhanced apoptotic potential, are compatible with an increased persistence in the 
blood and a promising antitumour activity. 
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1. Introduction 
The female hormone estradiol (E2 in Fig. 1) plays a critical role in controlling the female 
reproductive system. One of its many functions is to regulate the proliferation and 
differentiation of the healthy breast epithelium. Therefore it is not surprising that this 
molecule is involved in two-thirds of breast tumours, the second most deadly cancer for 
women. These hormone-dependent cancer cells (ER+ cases) exhibit a higher accumulation of 
the estrogen receptor (ER), a transcription factor of the thyroid/steroid superfamily, which can 
be found in two different isoforms: ERα and ERβ ((Shiau et al., 1998), (Gustafsson, 1999)). 
However, a third of breast tumours are not hormone-dependent and are called ER negative 
(ER–). In the hormone induced pathway, when estradiol binds to its intranuclear receptor, it 
induces a typical conformational change in the protein structure, involving Helix 12 ((Shiau et 
al., 1998), (Jordan, 2003)). This enables the recruitment of coactivators and the dimerization 
of the ER. The homo/hetero-dimer then binds to small palindromic ERE sequences of DNA. 
This interaction allows the recruitment of transcriptional factors from the general transcription 
machinery around Polymerase II, and therefore initiates gene transcription and specific 
protein synthesis leading finally to cell proliferation. Thus, in ER+ tumours, the increased 
concentration of estrogen receptors favours cell multiplication. 
Since estradiol binding to its receptor seems to be a key step required for the proliferation of 
breast cancer cells, many molecules targeting this protein have been synthesized to counteract 
the action of estradiol ((Magarian et al., 1994), (MacGregor and Jordan, 1998), (Meegan and 
Lloyd, 2003)). The most popular and widely prescribed antiestrogen for hormone-dependent 
breast cancer is tamoxifen. Its active metabolite, hydroxytamoxifen (OH-Tam, in Fig. 1), acts 
as an antagonist in breast tissue. The dimethylaminoethoxy side chain interaction with 
Asp351 of the ER is held responsible for the observed antiestrogenic effect of 
hydroxytamoxifen, because it prevents the recruitment of coactivators, and favours the 
binding of corepressors instead. However, depending on the nature of the promoter to which 
hydroxytamoxifen binds, and the cellular context (e.g. the major type of ER (α or β) present in 
the tissue and the coactivator/corepressor ratio in the cell), this selective estrogen receptor 
modulator (SERM) can also act as an agonist. Thus, like estradiol, OH-Tam can induce 
beneficial effects such as maintaining bone density, but it also enhances endometrial tumour 
growth (MacGregor and Jordan, 1998). 
 
 
Fig. 1. Structures of Fc-diOH and DFO as compared to 4-hydroxy-tamoxifen (4-OH-Tam) 
and 17β-estradiol (E2). 
 
Unfortunately, the successful treatment of breast cancer by hydroxytamoxifen is also 
overshadowed by the fact that some hormone-dependent breast tumours do not respond to 
endocrine therapy, and others respond initially to the antihormonal treatment, but acquire 
resistance in the long term (Lewis and Jordan, 2005, Osborne, 1998). To those cases of 
intrinsic and acquired resistance, the insensitive ER– tumour cells have to be added to point 
out the limitation of hydroxytamoxifen. These cases highlight the dire need for new active 
molecules with broader therapeutic scopes. 
After the discovery of the potent anticancer activity of cis-platin (Rosenberg et al., 1965, 
Rosenberg et al., 1969), many similar metal coordination complexes have been proposed 
(Jakupec et al., 2003). Though highly cytotoxic, most of them faced problems of instability. 
Compared to metal coordination complexes, organometallic compounds should be more 
stable, because their metal–ligand bond has a stronger covalent character (Crabtree, 2005). 
Our approach was to add a potentially cytotoxic moiety, i.e. the robust organometallic group 
ferrocene, to the competitive bioligand hydroxytamoxifen scaffold. We have shown that 
attaching such a neutral and stable moiety enhanced the cytotoxicity of hydroxytamoxifen, 
and increased the lipophilicity of the compound to facilitate its passage through the cellular 
membrane. (Jaouen et al., 2000, Jaouen et al., 1996, Top et al., 1996, Top et al., 2003, 
Vessières et al., 2005). 
Among the various organometallic compounds we synthesised, two of them were singled out. 
Compound Fc-diOH (1,1-di(4′-hydroxyphenyl)-2-ferrocenylbut-1-ene, Fig. 1) is an analog of 
OH-Tam, where the tamoxifen β- aromatic benzyl ring has been replaced by the aromatic 
ferrocene moiety, and the amino side-chain has been replaced by a second hydroxyl group 
(Vessières et al., 2005). It is our most efficacious cytotoxic compound to date (IC50 ≈ 0.7 μM 
on MCF-7, 0.44 μM on MDA-MB231). In compound DFO (1,2-di(4′-hydroxyphenyl)-1-[4″-
(2″-ferrocenyl-2″-oxoethoxy)phenyl]but-1-ene, Fig. 1), the amino side-chain of OH-Tam has 
been changed into a carbonylferrocene moiety (Nguyen et al., 2007). DFO has shown a 
weaker antiproliferative activity towards cancer cells (IC50 ≈ 10 μM on MCF-7), but good 
affinity for the estrogen receptors (RBA ≈ 14% on ERα and ERβ), probably thanks to the 
additional hydroxyl group on the β-benzyl ring. Interestingly, both compounds are active 
against ER+ and ER– cancer cells, suggesting that they do not target only the ERs in cancer 
cells. 
Although Fc-diOH and DFO appear to be promising potential drugs, they still encounter the 
problem of bioavailibility, so common to active biomolecules discovered in laboratories, 
especially for phenols. Indeed, once injected in the bloodstream, the active molecule is often 
degraded or opsonized and removed from blood circulation by macrophages of the 
reticuloendothelial system. Hence, in order to increase the circulation time in the bloodstream 
and to enhance the probability of the molecule to extravasate in tumour tissues, we chose to 
protect the active molecule inside nanoparticles (NP). These drug carriers have hydrophilic 
polyethyleneglycol (PEG) chains at their surface, to reduce the opsonization process 
(Soppimath et al., 2001). They could transport and concentrate the antiproliferative agents in 
the tumours, because their size enables them to cross the gaps of the discontinuous 
endothelium of cancer cells, which are richly vascularised (Gabizon and Papahadjopoulos, 
1988). This method to improve the bioavailibility has already been used for many bioactive 
molecules, including tamoxifen (Hu et al., 2006, Shenoy and Amiji, 2005). 
Therefore, for a more targeted and effective drug delivery, Fc-diOH and DFO were loaded 
inside nanospheres (NS) and nanocapsules (NC). A nanosphere is a matrix of polymer into 
which the active molecules are trapped. A nanocapsule is a vesicular system, whose oily core 
traps and retains the active molecules, and is surrounded by a protective polymeric membrane 
(Fig. 2). The polymer chosen is a biodegradable poly(D, L-lactic acid), or PLA. It is 
covalently bound to hydrophilic PEG chains, which are at the surface of the NPs. The ability 
of the nanospheres and nanocapsules to modulate the antiproliferative activity of Fc-diOH 
and DFO was then assessed by in vitro biological evaluation. 
 
 
Fig. 2. Structures of the PEG-PLA nanosphere and nanocapsule. 
 
2. Materials and methods 
2.1. Chemicals 
Soy phosphatidylcholine Lipoïd S75
®
 (about 70% of phosphatidylcholine) was purchased 
from Lipoïd GmbH (Germany). Miglyol 810N was kindly provided by Hüls (Germany). 
Poly(D, L-lactide) PLA50 of MW 42 kDa was supplied by Phusis (France). PLA-PEG (D, L-
PLA50 MW 45 kDa and PEG MW 5 kDa) was synthesized and characterized as previously 
described (Gref et al., 1995). 
Compounds Fc-diOH and DFO were prepared according to literature procedures (Top et al., 
2003) and (Nguyen et al., 2007). 
The solvents were analytical grade, and all other chemicals were commercially available at 
reagent grade. Water was purified by reverse osmosis (MilliQ, Millipore
®
). 
 
2.2. Preparation of PEG-Coating Nanoparticles 
The preparation of nanospheres (NS) according to Fessi et al. (1989) was based on interfacial 
deposition of preformed polymer, following solvent displacement. 
Briefly, 20 mg of polymer or copolymer were dissolved in 1 mL of acetone containing 10
−3
 M 
of Fc-diOH or DFO, and rapidly dispersed into 2 mL of demineralised and sterilised water, 
followed by acetone evaporation under nitrogen flow for 2 h, and left overnight before use. 
In the case of the nanocapsules (NC), only 5 mg of preformed polymer was dissolved in 1 mL 
of acetone. An amount of 2,1 mg of Fc-diOH or 5,9 mg of DFO was dissolved in a mixture 
of lipophilic surfactant (Lipoïd S75
®, 66 mg/mL of acetone) and oil (Miglyol 810, 25 μL/mL 
of acetone). An amount of 25 μL of this preparation was added to the organic phase, before 
dispersion in water. 
Control particles without Fc-diOH and DFO were prepared under the same conditions. 
 
2.3. Physicochemical characterization of nanoparticles 
The size of nanoparticles was measured by QuasiElastic Laser Light Scattering using a 
Nanosizer N4 Plus (Coulter Electronics, Florida, USA). The potential measurements (ς 
potentials) were determined with a Zetasizer 4 (Malvern Instruments, UK) after dilution of 
NS or NC suspensions in 1 mM KCl in a 1:2 volume ratio (NP suspension/1 mM KCl). 
 
2.4. Measurement of encapsulation efficacy 
Incorporation efficiency of the ferrocenyl derivatives was expressed both as encapsulation 
rate (w/w ratio) and percentage of encapsulation (%). The amount of Fc-diOH and DFO 
associated with the drug carriers was indirectly determined by UV–vis spectroscopy (Jenway 
6405 UV–vis spectrometer). These values were calculated as the difference between the total 
amount of Fc-diOH or DFO used to prepare the loaded nanoparticles and the amount of free 
molecules in the aqueous phase, after separation by centrifugation (60,000 g, 1 h, 4 °C) for 
nanospheres, or by ultrafiltration/centrifugation (450,000 g, 1 h, 4 °C) using Millicon 
eppendorfs (10,000 NMWL, Millipore
®
, France) for nanocapsules. The concentrations of Fc-
diOH and DFO in the aqueous phase after centrifugation were determined by the absorbance 
at 304 nm for Fc-diOH and at 276 nm for DFO. This spectroscopic method was validated for 
drugs with concentrations between 1 and 100 μM. 
 
2.5. Cell culture and transcription measurements 
We used a method based on the capacity of free and encapsulated antiestrogens to inhibit 
estradiol-induced transcription in MELN cells, as previously described (Ameller et al., 
2003b). MELN cells are MCF-7 cells stably transfected with a construct in which the 
luciferase (LUC) reporter gene is placed downstream of an estrogen responsive element 
(ERE) linked to the minimal β-globin promoter (ERE-β-globin-LUC). MELN and MCF-7 
cells were cultured in DMEM (DMEM Biological Industries, Inc., Kibbutz Beit Haemek, 
Israel) supplemented with L-glutamine (2 mM), penicillin (50 UI/mL), streptomycin (50 
UI/mL) and 10% FCS and maintained at 37 °C, with 5% CO2 in a humidified atmosphere. 
Before steroid treatment, MELN cells were grown for 3 days in phenol red free DMEM 
containing 10% charcoal-stripped FCS. Under these experimental conditions, 0.1 nM of 17β-
estradiol (E2) was found to induce the maximum LUC transcription. In order to evaluate the 
release of Fc-diOH and DFO from the formulations, NCs and NSs containing Fc-diOH or 
DFO were added to the culture medium containing 0.1 nM E2. After a total incubation time of 
18 h at 37 °C, cells were collected, rinsed and lysed in 250 μL of LUC buffer (25 mM 
Tris/HPO4 at pH 7.8, 10 mM MgCl2, 1% Triton X100, 15% glycerol, 1 mM EDTA, 1 mM 
DTT). Protein concentration was determined by the Biorad assay (Bio-Rad GmbH, Munich, 
Germany). Quantification of LUC activity was performed in triplicate in a luminometer (TD 
20/20, Tuner Designs, Sunnyvale, CA), after injection of the LUC buffer (100 μL) 
supplemented with 100 mM ATP and 87 μg of luciferin/mL to 100 μL of cellular extract. 
Each experiment was repeated twice. 
 
2.6. Cell cycle analyses and apoptosis estimation 
MCF-7 cells (2 × 10
5) were exposed or not to the free or the encapsulated drugs (1 or 10 μM) 
during 48 h and 72 h. The cells were washed twice in cold phosphate-buffered saline (PBS), 
pelleted and suspended in ice-cold ethanol (80% in MilliQ water). In some experiments, 10 
μM α-tocopherol was added for 1 h to the cell medium prior to further treatment. Fixed cells 
were then centrifuged and resuspended in PBS at 25 °C containing 100 μg/mL RNase A 
(Roche Molecular Biochemicals, Meylan, France) and 20 μg/mL propidium iodide (PI, 
Sigma–Aldrich) for 30 min at 37 °C. Cells were further analysed with a FACS Calibur 
(Becton–Dickinson, Le-Pont-de-Claix, France) equipped with an argon laser tuned at 488 nm 
and data were obtained with the CellQuest 1.2.2 and the ModFit LT 1.01 softwares (Becton–
Dickinson). 
 
3. Results 
3.1. Characterization of NPs 
The size and the zeta (ς) potential of both empty NSs and NCs loaded with the organometallic 
compounds Fc-diOH and DFO are summarized in Table 1. The ς potential indicates the 
surface charge of the NP. While the size of the NCs was in the range of 150–200 nm, that of 
the NSs was three times smaller. The incorporation of the drug did not modify this parameter 
for either formulation. This was not the case for the ς potential: the decrease of the ς potential 
of Fc-diOH- and DFO-charged NSs, as well as the increase of NC ς potential indicate that 
some amount (though small) of the compounds were adsorbed at the NP surface. Indeed, the ς 
potential of the aqueous suspension of Fc-diOH and DFO at 1 mM was definitely negative, 
and measured as −35.5 ± 5.2 and −36.6 ± 0.5 mV, respectively. These values are lower than 
the ς potential of the unloaded NSs. Hence, if the organometallic compounds were adsorbed at 
the surface of the NSs, the ς potential of the loaded NSs should decrease. On the other hand, 
the ς potential of the free compounds are higher than those of the empty NCs. Therefore, we 
expected the ς potential of the loaded NCs to increase, if the organometallic compounds were 
adsorbed at the surface of the NCs. 
  
Table 1. Characterization of the nanoparticles (mean values ± S.D., n = 6) 
 Mean 
diameter 
(nm) 
Zeta potential 
(mV) 
Encapsulation 
efficiency 
(μg/mg 
polymer) 
Encapsulation 
yield (%) 
Nanospheres  
 
 
Empty 50 ± 18 −1.1 ± 0.5 – – 
Fc-diOH 52 ± 16 −7.3 ± 0.6 198 ± 4 95 ± 2  
 
DFO 56 ± 18 −2.9 ± 0.4 255 ± 20 93 ± 7 
 
 
Nanocapsules  
 
 
Empty 178 ± 77 −73.5 ± 1.4 – – 
Fc-diOH 180 ± 56 −44.0 ± 0.7 8 ± 1 83 ± 4 
DFO 130 ± 35 −57.8 ± 4.0 25 ± 1 93 ± 5 
 
The encapsulation yield of both molecules in the NSs was higher than that in the NCs. The 
maximum concentrations of encapsulated Fc-diOH and DFO were similar in the NSs (1 mM) 
and were estimated at 70 μM and 160 μM in the NCs respectively. The encapsulation 
efficiency and encapsulation yield of both types of NP showed that the organometallic 
compounds have a high affinity for the copolymer. Nevertheless, NC had a tendency to 
incorporate a lower concentration of both compounds, a feature characteristic of such 
nanoparticles, because of the reduced oil solubility (Ameller et al., 2003b). 
 
3.2. Modulation of the antiestrogenic activity by ferrocifen-loaded NP 
We wondered next about the biological activity of the NPs. In a previous work, we showed 
that unloaded PEG/PLA NPs have no inhibitory activity on the luciferase gene expression in 
MELN cells (Ameller et al., 2003b). As shown in Fig. 3, free Fc-diOH had a weak inhibition 
on estradiol-induced transcription in MELN cells at 16 h, with an IC50 value about 100-fold 
that of OH-Tam. However, the trapped Fc-diOH has an even weaker ability to inhibit the 
expression of luciferase than the free compound at 16 h. This feature suggests that only a 
limited amount of drug was released from the NPs. Surprisingly, the type of NP does not 
seem to affect the transcription inhibition activity. 
 
 
Fig. 3. Inhibitory capacity of free and PEG/PLA NS and NC loaded with Fc-diOH on E2-
mediated transcription. MELN cells (10
6
) grown in phenol red free medium for 3 days were 
treated in triplicates during one night (16 h) with increasing concentrations of Fc-diOH, free 
and entrapped in either NS or NC as described in Materials and Methods. In the control 
experiment, E2-induced transcription (at 1 nM) was estimated as 100%. It corresponds to a 8–
9 fold increase as compared to the basal level of transcription (obtained without E2, but only 
vehicle). After harvest and lysis, luciferase activity was measured. Data are expressed as 
mean% ± S.D. (n = 3) of inhibition of the E2-induced luciferase (LUC) activity. 
 
Data from Fig. 4 indicate that DFO has a better antiestrogenic activity than compound Fc-
diOH. Precisely, its luciferase inhibition activity is ten times stronger than that of Fc-diOH. 
Again, both DFO-loaded NCs and NSs have a weaker transcription inhibition activity than 
free DFO. Interestingly, DFO released from the NC has an inhibitory activity somewhat 
similar to that of Fc-diOH trapped in the NPs (data from Fig. 3 compared to data from Fig. 
4). However, in the case of DFO, the type of NP in which the molecule is encapsulated seems 
to influence its activity. Comparatively, the DFO-loaded NS inhibits the luciferase activity 
100 times more than DFO trapped in a NC. This suggests that NCs release DFO more slowly 
than NSs, and this feature is even more striking at high concentrations (10
−7–10−6 M). 
 
 
Fig. 4. Inhibitory capacity of free and PEG/PLA NS and NC loaded with DFO on E2-
mediated transcription. MELN cells were treated as in Fig. 3 with free and NS, NC-trapped 
compound DFO. Results are expressed as in Fig. 3. 
  
3.3. Activity of ferrocifen-NP on cell cycle and apoptosis 
We then wanted to know if these nanosystems behave differently towards MCF-7 cell 
proliferation. Flow cytometry experiments were carried out at 48 h and 72 h with both free 
and encapsulated Fc-diOH and DFO at 1 μM and/or at 10 μM. Data (FACS analysis) are 
summarized in Table 2, Table 3. Both empty NSs (Table 2) and empty NCs (Table 3) had no 
effect on the cell distribution as already observed (Renoir et al., 2006). Interestingly, the 
number of cells in the S-phase of the cycle has increased more clearly with Fc-diOH than 
with DFO, whether the compounds were trapped or not in NS. At a similar concentration, 
once trapped in the NS, DFO had a strong capacity to arrest cell cycle in the G0/G1 phase at 
48 h, unlike the free drug. This effect was no longer observed at 72 h, suggesting maybe some 
instability of DFO, which is protected only as long as it stays encapsulated. 
 
Table 2. FACS analysis on MCF-7 cells exposed to free and encapsulated ferrocene 
derivatives in nanospheres (NS) of PEG/PLA 
 G0/G1  S  G2/M  Sub G1  
 48 h 72 h 48 h 72 h 48 h 72 h 48 h 72 h 
Control 69 79 14 12 14 8 3 2  
Fc-diOH 10 μM 63 54 24 37 6 6 11 10  
DFO 10 μM 66 62 13 18 19 16 5 10  
NS Fc-diOH 64 52 25 38 8 7 8 17  
NS DFO 80 66 10 20 9 9 5 15  
Empty NS 70 73 13 11 14 9 2.5 3  
 
  
Table 3. FACS analysis on MCF-7 cells exposed to free and encapsulated ferrocene 
derivatives in nanocapsules (NC) of PEG/PLA 
 G0/G1  S  G2/M  Sub G1  
 48 h 72 h 48 h 72 h 48 h 72 h 48 h 72 h 
Control 67 72 16 15 17 13 1.1 1.25 
Fc-diOH 1 μM 36 44 38 36 25 19 4 3  
DFO 1 μM 66 73.5 16 14 17 12 2 2 
NC Fc-diOH 49 59 28.5 24 22 16 1.6 2.3 
NC DFO 63 65 17 21 20 12 1.1 3 
Empty NC 66 69 18 19 16 15 1.6 2 
 
Interestingly, an increase of cells in apoptosis was noticed after cell exposure to both free Fc-
diOH and DFO. This fate was stronger in the case of cell incubation with the trapped 
compounds. Altogether, data from Table 2 suggest that at 10 μM, Fc-diOH has a greater 
capacity to arrest the cell cycle in the S-phase than DFO. They have comparable ability to 
induce apoptosis in MCF-7 cells and this potency is enhanced and delayed by entrapment in 
PEG/PLA nanospheres. 
We also compared the activity of Fc-diOH/DFO-loaded NCs on the cell cycle. Since the 
encapsulation loading was weaker in the NCs than in the NSs, MCF-7 cells were exposed to 
weaker drug concentrations in the case of the NC experiments, in order to avoid too high an 
amount of polymer in the cell culture. Results presented in Table 3 clearly indicate that Fc-
diOH at 1 μM, whether free or encapsulated in the NCs, arrests cell cycle in the S-phase, and 
to a more limited extent in the G2/M phase. This feature is less clearly observed at 10 μM, a 
concentration which rather induces apoptosis (see Table 4). Additionally, a smaller number of 
cells in apoptosis were noticed after 48 h when the compounds were encapsulated, hence 
suggesting again the delay induced by the nanovectors. At this low concentration, free DFO 
at 1 μM had no significant effect on MCF-7 cells, contrary to the encapsulated drug which 
slightly increased the number of cells in the S-phase. 
  
Table 4. Effect on free radical inhibition by α-tocopherol (α-toco) on MCF-7 cells exposed to 
free compounds Fc-diOH and DFO 
 G0/G1  S  G2/M  Sub G1  
 48 h 72 h 48 h 72 h 48 h 72 h 48 h 72 h 
Control 65 67 20 18 15 12 2.25 1.9 
Fc-diOH 10 μM 55 59 36 31 7 9 8 7 
DFO 10 μM 72 71 14 15 9 11 6.7 7.7 
α-toco 54 67 24 18 21 14 3.9 3.9 
Fc-diOH + α-toco 52 64 39 27 8.5 8.6 3.5 4.7 
DFO + α-toco 71 72 14.5 14 12 13 5.9 5.6 
 
3.4. Influence of α-tocopherol on cell cycle and apoptosis 
It has been suggested that OH-Tam at high concentrations may induce the production of 
reactive oxygen species (ROS) in breast cancer cells (Obrero et al., 2002). Similarly, 
ferrocene derivatives have also been suspected of producing ROS ((Joy et al., 1989), (Osella 
et al., 2000), (Tabbi et al., 2002)). We next examined if the effects of the ferrocene derivatives 
observed in MCF-7 cells could imply ROS production. Similar experiments to those 
described in Table 3 were performed in the presence or absence of the antioxidant α-
tocopherol. Data from Table 4 suggest that α-tocopherol alone has practically no effect on the 
MCF-7 cell cycle in the experimental conditions, although it slightly induced apoptosis. 
However, we predicted that α-tocopherol would decrease apoptosis of cells exposed to Fc-
diOH and DFO. Indeed, in the presence of α-tocopherol, the number of cells in subG1 
dropped from 7 to 4.7, and from 7.7 to 5.6, respectively, after 72 h of treatment. These data 
also indicate that DFO could have a dual effect on MCF-7 cells, an antiproliferative effect 
through its inhibitory capacity towards ERα activation and downstream consequences, and the 
capacity to produce free radicals. 
 
4. Discussion 
The coupling of organometallic moieties tethered to SERMs has led to the synthesis of 
various types of compounds showing variable affinities for the two main ER isoforms ERα 
and ERβ (Jaouen et al., 2000, Jaouen et al., 1996, Top et al., 1996, Top et al., 2003, Vessières 
et al., 2005). In such a program, a ferrocenyl substituent has been tethered to the 4-hydroxy-
tamoxifen scaffold, the active metabolite of tamoxifen (Top et al., 2001, Top et al., 2003). 
Ferrocene is lipophilic, compact, and stable in non-oxidizing media. Its derivatives have 
shown some antitumour potential, when oxidized to the ferrocenium salt (Osella et al., 2000, 
Tamura and Miwa, 1997), albeit at rather high concentration (0.1 mM). Amongst the large 
variety of ferrocenyl derivatives of 4-OH-Tam created in our laboratory, compounds Fc-
diOH and DFO displayed antiproliferative activity on both estradiol-dependent (MCF-7) and 
independent (MDA-MB-231) breast cancer cell lines, probably due to ER-independent 
cytotoxicity of the compounds. 
In the present work, we have designed two types of nanovectors, aiming at the in vivo 
delivery of insoluble anticancer molecules. We took advantage of previously well established 
formulations based on the copolymer PEG/PLA, which proved to be capable of incorporating 
high concentrations of a SERM like 4-OH-Tam (Renoir et al., 2006) and a pure antiestrogen 
like RU58668 (Ameller et al., 2003a, Ameller et al., 2003b). Both organometallic compounds 
Fc-diOH and DFO were incorporated in these formulations at a high yield, although the NS 
incorporated higher concentrations than the NC. The size of the resulting NPs were within the 
range of the gaps in the discontinuous cancerous endothelium, and thus they are possible 
vectors for the organometallic bioligands. 
Both compounds showed efficiency in inhibiting estradiol-induced transcription in ER+ breast 
cancer cells, arresting cell cycle, and inducing apoptosis in the same cells. A great benefit of 
such devices is their endocytosis ability, leading to the delivery of their trapped drug inside 
the cell (Gabizon and Papahadjopoulos, 1988). They have, among others, the advantage of 
protecting the drugs against hydrolysis and oxidation. The synthesised nanovectors tend to 
promote the activity of Fc-diOH and DFO, maybe because encapsulation reduces their 
degradation. This observation is consistent with the results from the estradiol-induced 
transcription experiments on MELN cells and from the flow cytometry experiments. 
It is worthwhile to differentiate the results from antiestrogenic experiments on MELN cells 
and those from the FACS Analysis. The distinction lies in the concentrations used for each 
method. In the antiestrogenic experiments, the concentrations reached very small values such 
as 0.5 nM, whereas in the FACS experiments the concentrations were 1 μM and 10 μM. 
Therefore, in the MELN cells where the NPs were very diluted, a greater percentage of Fc-
diOH or DFO was liberated. This is a function of the partition coefficient between 
oily/polymeric medium and water for the NCs and the NSs. Moreover, diffusion of the active 
species through the polymeric matrix of the NSs was favoured for small concentrations. Thus, 
there was a greater percentage of organometallic compounds Fc-diOH or DFO liberated from 
the NPs in the estradiol-induced transcription experiments than in the flow cytometry 
experiments. So the relative reduced activity of the trapped compounds compared to the free 
ones was different according to the type of experiment. 
The mechanism of action of both organometallic compounds has been investigated, in order 
to better understand their antiproliferative effects. Fc-diOH and DFO must each follow 
different mechanisms, due to their structural differences. Indeed, it has been proposed that the 
ferrocene moiety in Fc-diOH acts as an intramolecular oxidation assistant (Hillard et al., 
2006b, Vessières et al., 2005). It is thought that the oxidation of iron (II) to iron (III) provokes 
the deprotonation of the phenol which is concerted with an intramolecular electron transfer to 
the ferrocenium moiety. The resulting organic radical species is oxidized again, followed by 
another proton abstraction from the ethyl group, resulting in a reactive quinone methide-type 
structure. This species can then form adducts with DNA, GSH, or proteins. It has been shown 
that the pattern ferrocene–C=C–phenol is required for this mechanism, being the electron 
carrier π-system. However, in the structure of DFO, the ferrocene moiety cannot act as an 
intramolecular oxidation “antenna”, having no electron carrier system to link the ferrocene 
moiety to a phenol group. So the antiproliferative effect observed must follow another 
mechanism. It might involve the oxidation of the ferrocene to a ferrocenium salt and 
production of hydroxyl radicals via the Fenton process (Hillard et al., 2006a). 
Our experiments suggest that α-tocopherol does reverse the antiproliferative effect of both 
organometallic compounds, since the number of cells in subG1 dropped when the antioxidant 
agent was added. This result is consistent with our hypothesis that Fe plays an important role 
in inhibiting the proliferation of breast cancer cells. As a well-known antioxidant, α-
tocopherol could prevent the oxidation of Fe(II) into Fe(III), and also help to reduce the 
downstream production of ROS, thus lowering the number of cells in subG1. 
 
5. Conclusion 
Interest in nanovectors of highly cytotoxic compounds has fostered many drug formulations, 
such as the lipid-coated aggregates of the metal coordination complex cis-platin (Burger et al., 
2002). This article describes for the first time an efficient encapsulation of organometallic 
compounds, which should possess stronger metal–ligand bonds than metal coordination 
complexes. The ferrocene derivatives Fc-diOH and DFO have shown interesting cytotoxic 
effects on MCF-7 cells, which very likely involve ROS production. But since their water-
insolubility impedes their potential biological activity, both were successfully loaded at high 
yield in nanospheres and nanocapsules. Thanks to their appropriate physicochemical 
characteristics, the nanoparticles were able to deliver the water-insoluble compounds to 
cancer cells, and shield the active molecules from degradation by delaying their release. 
Furthermore, according to the metal introduced, organometallic compounds could offer 
different possibilities. For instance, the Fe of DFO may be converted into radioactive Re or 
Tc, without greatly changing the binding affinity with ERα and β. Then it would be possible 
to follow the bioavailibility of the labelled bioligands in the body, once released from their 
protective nanovectors. 
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